Future treatment for COPD: targeting oxidative stress and its related signal.
COPD is pathogenically associated with oxidative stress, which originates not only from cigarette smoke, but also from hypoxia, infection, inflammation, and ageing. It is the reason that therapeutic strategies aim at attenuation of oxidative stress, its sources, or intracellular signals and pro-inflammatory network of its downstream. This review discusses the pathogenesis of COPD and its current therapy in viewpoint of oxidative stress and further provides the perspectives for new treatment strategies in COPD and recent patents that could develop into novel therapeutics.
Department of Respiratory Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.
Hiroo
H
Wada
Hajime
H
Takizawa
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D016718:Arachidonic Acid / Q000494:pharmacology; D001691:Biological Therapy / Q000639:trends; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D018384:Oxidative Stress; D010330:Patents as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000628:therapy*; D015398:Signal Transduction / Q000276:immunology
D000975:Antioxidants; D018836:Inflammation Mediators; D016718:Arachidonic Acid